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he prevalence of cancer is expected to incre-
ase worldwide over the next decade.1 The
incidence of new cases is expected to esca-
late from 11.3 million in 2007 to 15.3 million in
2030.1 This increase may be 10-fold higher among
the elderly (persons aged ≥65 years) than among
younger individuals.2 The treatment of cancer is
already the foremost driver of increased healthcare
costs in many countries.3 In the United States,
increasing unit treatment costs per patient dominate
as the driver for overall healthcare costs,3 despite- see front matter
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Open access under CC BY-NC-ND license.a decrease in overall cancer prevalence from 1999 to
2010.4 The US budget for cancer drugs as deter-
mined by sales rose fourfold from 1998 to 2008;
most of these drugs are high-cost biologic drugs.5 For
example, US Medicare spending on drugs adminis-
tered in a physician’s office, most of which were
cancer treatments, rose 267% from 1997 to 2004,
while overall Medicare spending rose only 47%.3
Many patients also may have faced escalating health-
care costs in excess of inflation, including insurance
premiums (131% increase since 1999) and the
potential for bankruptcy in some cases (Figure 1).3
It has been estimated that the percentage of the US
family budget spent on healthcare in 2010 is identi-
cal to that spent on food.6 This places a significant
burden on patients and their families.
The economic burden of cancer treatment is not
limited to the United States. In France, the cost of
cancer therapies has been doubling every 4 years,
rising from €474 million to €975 million from 2004 to
2008.3 A significant driver of these increased health-
care expenditures may be treatment costs for aging
patients with cancer3,7 or the longevity of this pop-
ulation increasing with economic expansion.7 This
article will highlight specific economic considerations
with biosimilars. Specifically, it provides insight into
factors affecting the potential impact of biosimilars on
healthcare costs. Considerations that are highlighted3-S20 S13
Figure 1. Escalating costs of insurance premiums and
employee healthcare contributions compared with
employee earnings and inﬂation, 1999 to 2010. Cornes
P.3 With kind permission from Springer ScienceþBusiness
Media: Targeted Oncology, The economic pressures for
biosimilar drug use in cancer medicine, 7, 2012, S59,
Cornes P, Figure 1.
D. Henry and C. TaylorS14include pricing and reimbursement, as well as avail-
able types of pharmacoeconomic methodologies that
may be applicable to biosimilars (eg, cost-minimization
and cost-effectiveness analyses).HOW HAS THE BURDEN OF ESCALATING
TREATMENT COSTS BEEN ADDRESSED SO
FAR?
Because of escalating healthcare costs, many coun-
tries have enacted legislation authorizing the manu-
facture and distribution of small-molecule generic
drugs. In many countries, including the United King-
dom, Germany, Sweden, France, and the Philippines,
small-molecule generic drugs substantially reduced
costs compared with their reference small-molecule
drug. In many cases, the cost-savings were upwards of
50%.8 In the United States, the use of generics has
increased since the initial enactment of the Drug Price
Competition and Patent Term Restoration Act (Hatch-
Waxman Amendments) in 1984. It is estimated that
drug costs were reduced by $1.32 billion annually foreach 1% increase in generic prescribing, and generics
saved Medicare part D and its beneficiaries $33 billion
in 2007.3,9
By 2016 approximately $64 to $67 billion worth
of total global sales of biologic therapies will be
coming off patent in the United States and the
European Union (EU); a number of these are used
to treat cancer.10,11 According to one estimate, an
annual savings of €1.6 billion per year has been
predicted for the EU if biosimilars to five patent-
expired biologic drugs are successfully developed.3
Because of the high treatment costs associated with
biologic drugs,5 several governments including those
of the United States, EU, Japan, and Korea have
instituted approval pathways for the development
and commercialization of biosimilars.9,12 Biosimilars
are not “generic” versions of currently approved
biologics. A biosimilar is a biologic drug that is
highly similar (ie, the two drugs have the same drug
target, mechanism of action, and primary structure
among other molecular similarities) to an approved
reference biologic drug (originally patented drug or
innovator product).13
Biosimilars have the potential to lower costs.
However, due to their higher manufacturing and
development costs, decreases are likely to be smaller
in magnitude compared with generics.9,14 Biosimi-
lars may increase patient access to potentially val-
uable therapies.9 In Germany, approximately one-
third of prescriptions for the granulocyte colony-
stimulating factor (G-CSF), filgrastim, were for its
biosimilar in 2009.15 Using the biosimilar over the
reference biologic drug resulted in significant sav-
ings; €1203.5 for the original filgrastim versus
€867.8 for its biosimilar (Po.0001) according to
one estimate.16 In the United States, projected sav-
ings from biosimilars range from $3.0 to $4.5 billion
annually, and up to $378 billion over the next two
decades.3
The uptake of biosimilars in US oncology practi-
ces (and other areas where they are emerging)
ultimately may depend on several considerations,
including pharmacovigilance and safety profiles,9,17
the education of healthcare professionals and
patients,9 and affordable pricing.9 The potentially
lower cost of biosimilars may improve patient access
to care and contribute to a shift in treatment
strategies. In the United Kingdom, Germany, and
the Netherlands, the availability of a lower cost
biosimilar to G-CSF correlated with 10% to 20%
increased use of a G-CSF agent. Along with the
increase, G-CSF was used earlier in the course of
therapy, resulting in a shift of its use as a secondary
to primary prophylactic agent against febrile neutro-
penia.18 This is an example of how the affordability
of biosimilars has the potential to provide patients
with greater access to biologic drugs.
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CONSIDERATIONS MAY AFFECT THE USE AND
INCORPORATION OF BIOSIMILARS INTO
CLINICAL PRACTICE?
As biosimilars emerge in the United States and EU
after patents expire for several biologics,10 they may
offer different opportunity costs to patients and
healthcare systems in the treatment of cancer.3 An
opportunity cost is a benefit foregone when a given
option is selected over its next best alternative. In
healthcare, opportunity cost analyses consider the
level of resources currently devoted to a therapy that
would otherwise be used in another manner.19
These analyses typically are performed by payers.
Because of their comparability to their respective
reference biologic drugs, biosimilars may increase
patient access to treatment, while reducing oppor-
tunity costs for additional therapeutic options or
other expenses.9,19
Pharmacoeconomic considerations within health-
care systems may factor into the use of biosimilars
for many countries.20 An increasing number of
countries have developed guidelines that specify
standards for conducting economic evaluations to
be included in reimbursement applications.21 The
pharmacoeconomic studies that are the most perti-
nent to biosimilars will depend on the properties of
the biosimilar and reference biologic. In this review,
four types of pharmacoeconomic analyses are con-
sidered20 that may be applicable with respect to
biosimilars; cost-effectiveness, cost-minimization,
cost-utility, and cost-benefit (Table). Appropriately
designed and powered clinical studies demonstrat-
ing highly similar efficacy and safety profiles
between a biosimilar and the reference biologic
allow a cost-minimization analysis that would help
determine the least expensive therapy (Figure 2).
Few articles are available in the literature regard-
ing pharmacoeconomic analyses of biosimilars, espe-
cially biosimilars of monoclonal antibodies. A limited
number of cost-minimization analyses have beenTable. Deﬁnitions of Selected Frequently Used Pha
Type of Analysis
Cost-effectiveness Comparison that balances a s
beneﬁts to the quality of li
Cost-minimization Comparison of multiple drugs
the least expensive therapy
Cost-utility Ratio between the cost of a h
produces in terms of numb
Cost-beneﬁt Determines whether an inves
feasibility) and provides a b
expected cost of each opti
whether the beneﬁts outw
programs are a classic examdocumented for biosimilars in certain countries
where they are in use, such as the United King-
dom.20 But, in the United States, cost information is
not available because biosimilars are not yet
approved. Of note, the US Food and Drug Admin-
istration (FDA) recently approved Teva’s tbo-filgras-
tim, a short-acting G-CSF product. Tbo-filgrastim is
marketed in Europe under the trade name Tevagras-
tim as a biosimilar G-CSF. Since a US biosimilar
pathway was not in place at the time of FDA
submission, Teva will market tbo-filgrastim as an
innovator product in the United States.22 Payers
may utilize cost-minimization analyses that also can
be used to help other healthcare professionals
identify treatment strategies that are beneficial to
patients in terms of therapeutic value and cost. For
example, a recent study compared the benefits of
the use of low-cost versus high-cost bypassing agents
that have demonstrated similar efficacy profiles in
hemophilia surgical patients susceptible to inhibi-
tors. (Bypassing agents are coagulation factor prod-
ucts that may avoid the insufficient activation of
factor X in typical hemophilia.23) The model used by
the study authors examined drug cost and dosing
over 14-day surgical procedures. The use of the
lower-cost bypassing agent resulted in a decrease
in total drug cost of 58% and a cost-savings of more
than $470,000.24 As biosimilars emerge and are
accepted by clinicians, cost-minimization models
may provide insight into the value of biosimilars in
terms of cost and clinical benefit.FACTORS THAT MAY IMPACT
PHARMACOECONOMIC ANALYSES OF
BIOSIMILARS
The value of a biosimilar to society must be
viewed from the perspective of healthcare providers,
patients, and payers, and may be affected by several
variables. Concentration on costs is not sufficient in
itself, instead it is factored into an analysis that isrmacoeconomic Analyses
Deﬁnition
ingle unit of cost against a single unit of risks or
fe extended to the patient20
of equal efﬁcacy and equal tolerability to identify
20
ealth-related intervention and the beneﬁt it
er of years lived in full health20
tment or policy decision is sound (justiﬁcation/
asis for evaluating policies by comparing the total
on against the total expected beneﬁts, to see
eigh the costs, and by how much; vaccination
ple33
Figure 2. Cost-effectiveness plane. Ideally, most medications would fall in the upper right quadrant or in cases where
efﬁcacy is comparable and the medicine is less costly (eg biosimilars vs reference biologic drug), the points would be in the
second quadrant. Simoens.20 Reproduced with permission of Dove Medical Press in Clinicoecon Outcomes Res, 2011;3:29-
36, via Copyright Clearance Center.
D. Henry and C. TaylorS16designed to assess the contribution of a therapy to
improved patient well-being and health (Figure 3).3Figure 3. Factors that may be considered as part of the
evaluation of the value of a biosimilar by healthcare
community members. Cornes3; Zelentz et al9; Dranitsaris
et al11; Weise et al14; Simoens20; NYS Department of
Health25; Kliff26; Hoadley29; Ebbers et al.34Emergence of Second-Generation Biologics
The emergence of second-generation biologics (or
biologics that make improvements on existing bio-
logics through pegylation, alternative formulations,
or other means)14 may affect the value of not only
first-generation reference biologics, but also their
biosimilars. As research and development of biologics
in the oncology setting continues, newer, second-
generation biologic drugs may offer different clinical
properties compared with currently approved refer-
ence biologics. They may include new formulations,
different efficacy profiles and/or dosing regimens, or
reduced immunogenicity.11 A second-generation bio-
logic may have an improved efficacy and/or safety
profile, but if the efficacy and safety of a given
second-generation drug is comparable to the first-
generation drug or its biosimilar, a cost-minimization
analysis could be performed to identify the most
economical solution for patients and payers. In
contrast, cost-effectiveness comparison analyses
could be performed with novel biologics that have
different efficacy and/or safety profiles relative to
first-generation products or their biosimilars. The
results of pharmacoeconomic analyses that incorpo-
rate second-generation biologic drugs may affect the
value that biosimilars of first-generation reference
biologic drugs offer patients with cancer and health-
care providers. This may include the extent of
financial and opportunity costs offset by the
emergence of these therapies. For example, if a
second-generation biologic has improved efficacy,
the opportunity for the patient to have a better
outcome would possibly negate its higher cost. Inaddition, the emergence of second-generation bio-
logic drugs may affect the drug acquisition prices for
first-generation reference biologic drugs and their
biosimilars.Drug Acquisition Prices
Relative costs of biologic drugs also are reflective
of drug acquisition prices (eg, manufacturers’ whole-
sale list prices and additional costs less any dis-
counts).25 Differences in acquisition prices between
a biosimilar and its reference biologic drug may vary,
for example, due to differing research and develop-
ment costs for a given biosimilar compared with
another with the same reference biologic drug.20
Any differences potentially could affect cost-mini-
mization analysis results. Further, a price differential
for a biosimilar could be substantial when compared
Pharmacoeconomics of biosimilars S17with a reference biologic and may increase as bio-
similar pricing has the potential to fall with rising
market share.20 Hospitals may negotiate discounted
biosimilar pricing (or that of other drugs) with
manufacturers, creating competition in the distribu-
tion chain rather than direct price competition.20
These variables can factor into pharmacoeconomic
analyses within a given institution or when making
comparisons between institutions. Due to these
economic pressures, independent community oncol-
ogy practices—which may be more cost- and time-
efficient—are increasingly migrating toward the
hospital-based/owned structure.
Treatment Administration Settings
The cost and subsequent value of a biosimilar may
be affected not only by institutional discounting, but
also by the type of institutional setting. The admin-
istration of biologics and/or their biosimilars through
outpatient oncology clinics, which are traditionally
less costly settings than hospitals, potentially can
impact the value of a biosimilar and the results of
pharmacoeconomic analyses. For example, outpa-
tient oncology clinics may represent a lower-cost
treatment option to patients and payers for the
administration of expensive chemotherapeutics.
However, this dynamic is evolving, as reimbursement
to these centers is subject to changes in federal
funding levels, as seen in the recent sequestration
budget cuts in the United States to Medicare. Ulti-
mately, these patients may shift to the hospital
setting, where treatment administration costs are
higher.26 This would result in a potentially reduced
cost-minimization benefit to the payer and/or patient
for the reference biologic drug or its biosimilar.
Beneﬁts Via Reduced Opportunity Costs
Reduced costs in terms of development or services
associated with biosimilar use may lead to reduced
opportunity costs when healthcare providers pre-
scribe and administer biosimilars as opposed to
reference biologics. From a patient perspective, the
potential economic benefit of biosimilars may be
determined on the basis of reduced treatment costs
with highly similar efficacy to a reference biologic,
thereby reducing opportunity costs for other expe-
nses. All of the above considerations may provide
patients, healthcare providers, and payers with the
data and means for slowing increases in cancer treat-
ment costs, while maintaining a focus on patients.EVALUATING THE POTENTIAL ECONOMIC
BENEFITS OF BIOLOGICS AND BIOSIMILARS
Economic evaluations are one part of a body of
clinical evidence that can help inform the developmentand use of safe and cost-effective biologics and bio-
similars, while helping to optimize expenditure.20 They
may help healthcare community members synthesize
information about the effectiveness, potential limita-
tions, and costs of interventions as well as the value of
their benefits.27 In the United States, pharmacoeco-
nomic studies on public health policies have been
limited in scope to date; that said, certain advisory
bodies, like the Advisory Committee on Immunization
Practices, do explicitly consider economic evaluations
when making recommendations.27
Comparative Effectiveness Studies
Comparative effectiveness studies, where researchers
examine the available evidence about the benefit and
potential safety considerations of each therapeutic
choice for different groups of individuals from existing
clinical trials, clinical studies, and other research28 have
been used by several nations, including Australia,
Canada, Germany, and the United Kingdom.29 Each
nation using these studies has an agency charged with
undertaking comparative effectiveness studies and mak-
ing recommendations to government health pro-
grams.29 A prominent example of such an agency is
the United Kingdom’s National Institute for Health and
Clinical Excellence (NICE).29 A panel of experts drawn
from academia, public health, practicing physicians, and
other stakeholders, including consumer representatives,
evaluate newly approved drugs through systematic
reviews of available research and decide whether or
not the given biologic or its biosimilar is recommended
for reimbursement by the National Health System
(NHS).29 Drugs that are not recommended for reim-
bursement remain available to patients, but are not
covered by the NHS.29 Recommendations to the NHS
rely on a cost-effectiveness threshold.29 Most clinical
trials used for health authority registrations are not
designed for these types of comparisons.30
Cost-Effectiveness Studies
Unlike comparative effectiveness studies that focus
more on clinical outcomes,27 cost-effectiveness stud-
ies balance a single unit of cost against a single unit of
risk or benefit to the quality of life extended to the
patient (Table). This metric is known as the incre-
mental cost-effectiveness ratio (ICER), and is the
monetary cost of gaining an extra quality-adjus-
ted life-year from each treatment.3 Many countries
have adopted cost-effectiveness analysis models to
analyze the cost-benefit ratio of existing technologies
versus the advancement towards innovative new
products.31 The United Kingdom’s NICE and Austral-
ia’s Pharmaceutical Benefits Advisory Committee
report using preset thresholds when determining
the utility of technological advancements with
respect to treatment decision making.31 Fixed ICER
D. Henry and C. TaylorS18thresholds, which reflect the maximum cost per unit
of outcome that a healthcare payer will pay for
medicine, have now become part of the standard
for reimbursement in many countries, including
Australia, Canada, the United Kingdom, the Nether-
lands, New Zealand, the United States, and Sweden
(Figure 4). Therapies that exceed the ICER threshold
are unlikely to be recommended for reimbursement.3
Reference Pricing
Reference pricing is the price set by the payer for
a group of similar drugs based on a benchmark, or
the reference, price. The reference price may be
based on the lowest-cost drug in the group or can be
an average price of all drugs in that group. Reference
pricing is used in countries with national or provin-
cial health systems, such as Australia, New Zealand,
Belgium, Germany, Hungary, Spain, the Netherlands,
South Africa, and the Canadian province of British
Columbia. With this type of reimbursement system,
the consumer pays the difference between the
manufacturer’s price and the reference price.29
Generic reference pricing refers to a set of drugs
that are chemically equivalent, while therapeutic
reference pricing differs in that it includes drugs
that are therapeutically equivalent.29 The general
principle of therapeutic pricing is to include a set
of drugs that physicians would consider appropriate
for substitution for most patients.29 Not all drug
classes may be suitable, especially classes where
clinical evidence of interchangeability is limited.29
It has yet to be determined how the latter may have a
potential use with biosimilars and therapeutic com-
parisons to their reference biologic drugs.
Cost-Minimization Analyses
Cost-minimization analyses can be used to evaluate
the potential pharmacoeconomic benefits ofFigure 4. Range of threshold incremental cost-effective-
ness rations in selected countries (bars extend to upper
limit; calculated per life-year). QALY ¼ quality-adjusted
life-year. Simoens.20biosimilars. These studies compare products with
equivalent benefits to the patient, but with differing
costs to determine the most economical treatment
option.19 For example, a decision may be made to
introduce a biosimilar rather than its reference bio-
logic drug as it should provide the same benefit at a
lower cost.9 These studies have been conducted in
countries where biosimilars are already in use. Cost-
minimization analyses from two phase III trials for
biosimilars to epoietin alfa in patients with chronic
renal failure in the United Kingdom demonstrated
clinical equivalence for the biosimilar, epoietin zeta,
compared with epoietin alfa, and concluded that
epoietin zeta would yield equivalent efficacy in terms
of surrogate end points of correction and mainte-
nance of hemoglobin concentration that is econom-
ical according to a cost-minimization analysis.20 In
another study, cost-savings of ₤322 per patient over
an 84-day period were predicted in a cost-mini-
mization analysis for a biosimilar to filgrastim for the
prevention of neutropenia in patients with breast
cancer.20 The results of cost-minimization analyses,
although currently limited in number, may suggest a
role of biosimilars in helping to address escalating
cancer treatment costs while providing highly similar
efficacy and safety to patients with cancer.HOW MIGHT PHARMACOECONOMIC
ANALYSES CONTRIBUTE TO TREATMENT
DECISIONS?
Pharmacoeconomic analyses may help to inform
healthcare professionals regarding therapeutic
options that represent potentially beneficial and
economical alternatives for patients and healthcare
systems. With biosimilars, pharmacoeconomic anal-
yses findings are impacted by development and
manufacturing costs, monitoring and acquisition
costs, as well as the determination of potential
benefits to patients in terms of offsetting healthcare
expenses.20 For patients, a broader role for effective-
ness research in formulary and drug benefit design
may be advantageous, because decisions may be
driven by overall value as opposed to solely by
economics.29 As biosimilars emerge and potentially
become more widespread in clinical practice, addi-
tional pharmacoeconomic analyses may be per-
formed and yield additional data on the effects of
biosimilars on reducing cancer treatment costs,
shedding greater light on the potential pharmacoe-
conomic benefits of these agents. Ultimately, the
question may not be “Will biosimilars provide cost-
savings?” Instead, it may be “Will they be cost-
effective compared with their branded equivalents?”
As was the case in the EU, the adoption of
biosimilars in the United States will not be driven
ResultChallenge
Additional budget
available for underserved
therapy areas
Budgets for certain
therapy areas
inadequate
Cost-savings
from biosimilars
Additional budget
available for innovative
therapies
Innovative therapies
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from biosimilars
More patients have access 
to medicine
Treatment reserved
for only most severe
patients
Cost-savings
from biosimilars
Patients receive treatment
earlier in therapy
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for later in therapy
Cost-savings
from biosimilars
Potentially
Improved
Patient
Outcomes
Figure 5. Savings with biosimilars could allow reallocation of budget to facilitate optimal patient treatment. Zelenetz
et al9; Weise et al17; Gascon et al18; Walley et al.19
Pharmacoeconomics of biosimilars S19solely by monetary concerns, but by safety and
efficacy data.9,17 Savings from biosimilars also have
the potential to enable use of biologic drugs (in the
form of biosimilars) to patients who may not have
had access to biologic therapies previously, leading
to potentially improved patient outcomes which, in
turn, may have a positive effect on cost-effectiveness
models (Figure 5). Finally, the balance between the
need for increased access and innovative therapies is
a consideration that may be achieved through the
additional competition and potential cost-savings
associated with biosimilars.32CONCLUSIONS
The cost of cancer treatment is a leading driver of
global healthcare costs, in part due to the use of
expensive biologics. Biosimilars represent a poten-
tial opportunity to increase patient accessibility to
biological therapies and lower the cost of treatment
(Figure 5). The overall pharmacoeconomic evalua-
tion of biosimilars may be affected by several factors,
including their manufacturing and development
costs, potential effect on comparative safety and
efficacy of biosimilars to first-generation products
by second-generation biologic drugs, safety monitor-
ing costs, and institutional and/or government
pricing policies. While there are limited pharmacoe-
conomic analyses reported for biosimilars in general,
the cost-minimization studies reported for biosimi-
lars used as supportive therapy in the oncology
setting to date suggest biosimilars may have the
potential to lower cost while offering efficacy and
safety that is highly similar to their reference biologic
drugs. Patients may regard the value of a biosimilar
as that of an option that reduces the opportunity
costs for healthcare or other expenses. As thedevelopment and adoption of biosimilars continue
to increase in the EU and potentially the United
States and other countries, pharmacoeconomic anal-
yses may be useful in evaluating biosimilars of two
differing reference biologic drug products. As is the
case in the EU, the adoption of biosimilars in the
United States will not be driven solely by monetary
concerns, but by safety and efficacy data. As the use
of biosimilars increases, additional pharmacoeco-
nomic studies will provide evidence that helps the
community determine the cost-effectiveness of bio-
similars relative to other therapeutic options. Ulti-
mately, this information will be one part of a
package of evidence that helps inform overarching
treatment strategies.REFERENCES
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